CZ20011472A3 - Způsob přípravy mesylát- trihydrátové soli 1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu a meziprodukty vhodné pro tento způsob přípravy - Google Patents

Způsob přípravy mesylát- trihydrátové soli 1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu a meziprodukty vhodné pro tento způsob přípravy Download PDF

Info

Publication number: CZ20011472A3
Authority: CZ; Czechia
Prior art keywords: compound; tartrate; formula; benzyl; salt
Prior art date: 2000-04-28

Application number

CZ20011472A

Other languages

Czech (cs)

English (en)

Inventor

Joseph Philip Rainville

Terry Gene Sinay Jr.

Stanley Walter Walinsky

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-28

Filing date

2001-04-25

Publication date

2001-12-12

2001-04-25 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2001-12-12 Publication of CZ20011472A3 publication Critical patent/CZ20011472A3/cs

Links

238000002360 preparation method Methods 0.000 title claims abstract description 11
238000004519 manufacturing process Methods 0.000 title claims description 5
LKGCPYOBWLSCTK-UHFFFAOYSA-N methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O LKGCPYOBWLSCTK-UHFFFAOYSA-N 0.000 title abstract description 18
239000000543 intermediate Substances 0.000 title abstract description 3
QEMSVZNTSXPFJA-UHFFFAOYSA-N traxoprodil Chemical compound C1CC(O)(C=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 QEMSVZNTSXPFJA-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 47
238000000034 method Methods 0.000 claims abstract description 35
230000008569 process Effects 0.000 claims abstract description 22
125000006239 protecting group Chemical group 0.000 claims abstract description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 20
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
-1 alkyl ketone Chemical class 0.000 claims description 13
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
239000002585 base Substances 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 10
229910052783 alkali metal Inorganic materials 0.000 claims description 9
150000001340 alkali metals Chemical class 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 9
238000007327 hydrogenolysis reaction Methods 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
125000002252 acyl group Chemical group 0.000 claims description 8
125000006177 alkyl benzyl group Chemical group 0.000 claims description 8
125000003435 aroyl group Chemical group 0.000 claims description 8
125000006307 alkoxy benzyl group Chemical group 0.000 claims description 7
125000005103 alkyl silyl group Chemical group 0.000 claims description 7
239000012448 Lithium borohydride Substances 0.000 claims description 6
229940098779 methanesulfonic acid Drugs 0.000 claims description 6
238000003776 cleavage reaction Methods 0.000 claims description 5
NTBIYBAYFBNTCD-KBPBESRZSA-N dibenzoyl (2s,3s)-2,3-dihydroxybutanedioate Chemical group O=C([C@@H](O)[C@H](O)C(=O)OC(=O)C=1C=CC=CC=1)OC(=O)C1=CC=CC=C1 NTBIYBAYFBNTCD-KBPBESRZSA-N 0.000 claims description 5
230000007017 scission Effects 0.000 claims description 5
NTOIKDYVJIWVSU-WOJBJXKFSA-N (2r,3r)-2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-WOJBJXKFSA-N 0.000 claims description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
238000010511 deprotection reaction Methods 0.000 claims description 3
FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 3
239000012279 sodium borohydride Substances 0.000 claims description 3
229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
LAQVTDNUNJALJK-FCXVTQFRSA-N O.O.O.C[C@@H]([C@@H](OS(C)(=O)=O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1 Chemical compound O.O.O.C[C@@H]([C@@H](OS(C)(=O)=O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1 LAQVTDNUNJALJK-FCXVTQFRSA-N 0.000 claims description 2
230000008878 coupling Effects 0.000 claims description 2
238000010168 coupling process Methods 0.000 claims description 2
238000005859 coupling reaction Methods 0.000 claims description 2
235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
OCQAXYHNMWVLRH-QZTJIDSGSA-N (2r,3r)-2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical class O=C([C@@](O)(C(=O)O)[C@](O)(C(O)=O)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 OCQAXYHNMWVLRH-QZTJIDSGSA-N 0.000 claims 1
LUILKELNVBKKTG-ZOZJKLBQSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol;methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 LUILKELNVBKKTG-ZOZJKLBQSA-N 0.000 claims 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
229910052744 lithium Inorganic materials 0.000 claims 1
229910052751 metal Inorganic materials 0.000 claims 1
239000002184 metal Substances 0.000 claims 1
QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 abstract description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
229930195712 glutamate Natural products 0.000 description 11
239000000243 solution Substances 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
239000002002 slurry Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000012458 free base Substances 0.000 description 7
239000001963 growth medium Substances 0.000 description 7
230000009466 transformation Effects 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000000047 product Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
239000012299 nitrogen atmosphere Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 3
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000000324 neuroprotective effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
KNAXARAMJRQGRK-DLNZSANPSA-N (2R,3R)-2,3-dibenzoyl-2,3-dihydroxybutanedioic acid (2S)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-(4-phenylmethoxyphenyl)propan-1-one Chemical compound OC(=O)[C@](O)(C(=O)c1ccccc1)[C@](O)(C(O)=O)C(=O)c1ccccc1.C[C@H](N1CCC(O)(CC1)c1ccccc1)C(=O)c1ccc(OCc2ccccc2)cc1 KNAXARAMJRQGRK-DLNZSANPSA-N 0.000 description 2
LRXIEGZMKNGPLB-OAQYLSRUSA-N (2r)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-(4-phenylmethoxyphenyl)propan-1-one Chemical compound C1CN([C@H](C)C(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CCC1(O)C1=CC=CC=C1 LRXIEGZMKNGPLB-OAQYLSRUSA-N 0.000 description 2
YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
201000006474 Brain Ischemia Diseases 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
208000007101 Muscle Cramp Diseases 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000005392 Spasm Diseases 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
208000030886 Traumatic Brain injury Diseases 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
201000004810 Vascular dementia Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
208000029650 alcohol withdrawal Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000002253 anti-ischaemic effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
229960001270 d- tartaric acid Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
230000002964 excitative effect Effects 0.000 description 2
239000004060 excitotoxin Substances 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
229960001031 glucose Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000006340 racemization Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000012265 solid product Substances 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
239000007858 starting material Substances 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
150000003892 tartrate salts Chemical class 0.000 description 2
230000009529 traumatic brain injury Effects 0.000 description 2
LRXIEGZMKNGPLB-NRFANRHFSA-N (2s)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-(4-phenylmethoxyphenyl)propan-1-one Chemical compound C1CN([C@@H](C)C(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CCC1(O)C1=CC=CC=C1 LRXIEGZMKNGPLB-NRFANRHFSA-N 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical class CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
MWASGDJOVNIDEM-UHFFFAOYSA-N 3-amino-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N)C(=O)N(C)C2=CC=CC=C2C=1C1=CC=CC=C1 MWASGDJOVNIDEM-UHFFFAOYSA-N 0.000 description 1
206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
241000021559 Dicerandra Species 0.000 description 1
206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
229940099433 NMDA receptor antagonist Drugs 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005599 alkyl carboxylate group Chemical group 0.000 description 1
150000001414 amino alcohols Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012136 culture method Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
210000004199 lateral thalamic nuclei Anatomy 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000007557 neuronal destruction Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000002135 phase contrast microscopy Methods 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
150000004684 trihydrates Chemical group 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
235000020681 well water Nutrition 0.000 description 1
239000002349 well water Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

CZ20011472A 2000-04-28 2001-04-25 Způsob přípravy mesylát- trihydrátové soli 1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu a meziprodukty vhodné pro tento způsob přípravy CZ20011472A3 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20041700P	2000-04-28	2000-04-28

Publications (1)

Publication Number	Publication Date
CZ20011472A3 true CZ20011472A3 (cs)	2001-12-12

Family

ID=22741639

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20011472A CZ20011472A3 (cs)	2000-04-28	2001-04-25	Způsob přípravy mesylát- trihydrátové soli 1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu a meziprodukty vhodné pro tento způsob přípravy

Country Status (26)

Country	Link
US (1)	US6570018B2 (2)
EP (1)	EP1149831B1 (2)
JP (1)	JP2001354650A (2)
KR (1)	KR100432841B1 (2)
CN (1)	CN1211366C (2)
AR (1)	AR028377A1 (2)
AT (1)	ATE275130T1 (2)
AU (1)	AU781715B2 (2)
BR (1)	BR0101611A (2)
CA (1)	CA2345286C (2)
CZ (1)	CZ20011472A3 (2)
DE (1)	DE60105221T2 (2)
DK (1)	DK1149831T3 (2)
ES (1)	ES2225425T3 (2)
HK (1)	HK1040514B (2)
HU (1)	HUP0101725A3 (2)
ID (1)	ID30012A (2)
IL (1)	IL142706A0 (2)
IN (1)	IN191534B (2)
PL (1)	PL347299A1 (2)
PT (1)	PT1149831E (2)
RU (1)	RU2192415C1 (2)
SI (1)	SI1149831T1 (2)
TW (1)	TWI222440B (2)
YU (1)	YU27801A (2)
ZA (1)	ZA200103321B (2)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6743921B2 (en) *	2002-01-24	2004-06-01	Dsm Catalytica Pharmaceuticals, Inc.	Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CN105037221B (zh) *	2015-06-18	2017-05-10	吉林大学珠海学院	一种具有神经保护作用的化合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272160A (en) *	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
ATE215072T1 (de)	1995-08-11	2002-04-15	Pfizer	(1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol-methansulfonat trihydrat
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

2001
- 2001-04-18 YU YU27801A patent/YU27801A/sh unknown
- 2001-04-19 IL IL14270601A patent/IL142706A0/xx not_active IP Right Cessation
- 2001-04-20 IN IN357BO2001 patent/IN191534B/en unknown
- 2001-04-23 TW TW090109679A patent/TWI222440B/zh not_active IP Right Cessation
- 2001-04-23 US US09/840,668 patent/US6570018B2/en not_active Expired - Fee Related
- 2001-04-24 ES ES01303713T patent/ES2225425T3/es not_active Expired - Lifetime
- 2001-04-24 ZA ZA200103321A patent/ZA200103321B/xx unknown
- 2001-04-24 EP EP01303713A patent/EP1149831B1/en not_active Expired - Lifetime
- 2001-04-24 DK DK01303713T patent/DK1149831T3/da active
- 2001-04-24 PT PT01303713T patent/PT1149831E/pt unknown
- 2001-04-24 DE DE60105221T patent/DE60105221T2/de not_active Expired - Fee Related
- 2001-04-24 SI SI200130185T patent/SI1149831T1/ unknown
- 2001-04-24 AT AT01303713T patent/ATE275130T1/de not_active IP Right Cessation
- 2001-04-25 CZ CZ20011472A patent/CZ20011472A3/cs unknown
- 2001-04-26 BR BR0101611-3A patent/BR0101611A/pt not_active IP Right Cessation
- 2001-04-26 AU AU38897/01A patent/AU781715B2/en not_active Ceased
- 2001-04-26 ID IDP20010344D patent/ID30012A/id unknown
- 2001-04-26 AR ARP010101972A patent/AR028377A1/es unknown
- 2001-04-26 CA CA002345286A patent/CA2345286C/en not_active Expired - Fee Related
- 2001-04-27 KR KR10-2001-0022856A patent/KR100432841B1/ko not_active Expired - Fee Related
- 2001-04-27 HU HU0101725A patent/HUP0101725A3/hu unknown
- 2001-04-27 RU RU2001111948/04A patent/RU2192415C1/ru not_active IP Right Cessation
- 2001-04-27 CN CNB011171545A patent/CN1211366C/zh not_active Expired - Fee Related
- 2001-04-27 JP JP2001130684A patent/JP2001354650A/ja active Pending
- 2001-04-27 PL PL01347299A patent/PL347299A1/xx not_active Application Discontinuation
2002
- 2002-03-14 HK HK02101947.0A patent/HK1040514B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR0101611A (pt)	2002-01-15
YU27801A (sh)	2003-04-30
DE60105221T2 (de)	2005-09-15
PT1149831E (pt)	2004-11-30
HUP0101725A2 (hu)	2002-02-28
AU781715B2 (en)	2005-06-09
ZA200103321B (en)	2002-10-24
ES2225425T3 (es)	2005-03-16
EP1149831A1 (en)	2001-10-31
US20020016466A1 (en)	2002-02-07
IL142706A0 (en)	2002-03-10
TWI222440B (en)	2004-10-21
CN1322716A (zh)	2001-11-21
US6570018B2 (en)	2003-05-27
PL347299A1 (en)	2001-11-05
DE60105221D1 (de)	2004-10-07
CN1211366C (zh)	2005-07-20
DK1149831T3 (da)	2004-12-06
ID30012A (id)	2001-11-01
KR20010098924A (ko)	2001-11-08
AU3889701A (en)	2001-12-13
SI1149831T1 (en)	2005-02-28
AR028377A1 (es)	2003-05-07
HK1040514A1 (en)	2002-06-14
RU2192415C1 (ru)	2002-11-10
CA2345286A1 (en)	2001-10-28
IN191534B (2)	2003-12-06
JP2001354650A (ja)	2001-12-25
CA2345286C (en)	2004-11-09
KR100432841B1 (ko)	2004-05-24
EP1149831B1 (en)	2004-09-01
HK1040514B (zh)	2005-10-28
ATE275130T1 (de)	2004-09-15
HUP0101725A3 (en)	2003-04-28
HU0101725D0 (en)	2001-07-30

Publication	Publication Date	Title
EP1499589B1 (fr)	2007-05-02	Derives de n-¬phenyl(piperidin-2-yl)methyl\|benzamide, leur preparation et leur application en therapeutique
JP3390179B2 (ja)	2003-03-24	エーテルムスカリン様アンタゴニスト
CA2228752C (en)	2002-12-10	(1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate
CN1048247C (zh)	2000-01-12	神经保护的苯并二氢吡喃化合物
JP2695292B2 (ja)	1997-12-24	神経保護性３，４−ジヒドロ−（１ｈ）−キノロン化合物
RU2192415C1 (ru)	2002-11-10	Способ получения мезилат тригидрата 1-(4-гидроксифенил)-2-(4-гидрокси-4-фенилпиперидин-1-ил)-1-пропанола и промежуточные продукты
RU2203888C2 (ru)	2003-05-10	Способы получения метансульфонат тригидрата и d-(-)-тартратной соли (1s,2s)-1-(4-гидроксифенил)-2-(4-гидрокси-4-фенилпиперидин-1-ил)-1- пропанола
MXPA01004289A (en)	2002-06-05	Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl) -2-(4-hydroxy-4- phenylpiperidin -1-yl) -1-propanol and intermediates useful therefor
WO1997013769A1 (en)	1997-04-17	Disubstituted piperidine derivatives
MXPA01004288A (en)	2002-06-05	Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)- 2-(4-hydroxy-4- phenylpiperidin-1-yl)- 1-propanol
HK1070644A (en)	2005-06-24	Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol
MXPA98001149A (en)	1998-10-23	Metansulfonate of (1s, 2s) -1- (4-hydroxypenyl) -2- (4-hydroxy-4-phenylpiperidin-1-il) -1-propanoltrihydrate and use of mi